Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: Cohort study

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Hansson, Jonas ^a   Vasan, Ramachandran S ^b,c   Ärnlöv, Johan ^d,e   Ingelsson, Erik ^f   Lind, Lars ^a   Larsson, Anders ^b,c   Michaëlsson, Karl ^a   Sundström, Johan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b FRAMINGHAM HEART STUDY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

^e DALARNA UNIVERSITY   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

AGED; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FOLLOW UP; HEART INFARCTION; HUMAN; MALE; MORTALITY; PROTEIN FUNCTION; PROTEIN METABOLISM; RISK FACTOR; BLOOD; CAUSE OF DEATH; ENZYMOLOGY; EXTRACELLULAR MATRIX; LONGITUDINAL STUDY; METABOLISM; PROSPECTIVE STUDY; RISK; STROKE;

AGED; BIOLOGICAL MARKERS; CAUSE OF DEATH; COHORT STUDIES; EXTRACELLULAR MATRIX; HUMANS; LONGITUDINAL STUDIES; MALE; MATRIX METALLOPROTEINASE 9; MORTALITY; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK; STROKE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 79251636740     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016185     Document Type: Article

References (45)

1. Fong KM, Kida Y, Zimmerman PV, Smith PJ (1996) TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 2: 1369-1372.
2. Lijnen HR (2003) Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 33: 275-281.
3. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, et al. (2001) Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103: 2303-2309.
4. Belvisi MG, Bottomley KM (2003) The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Inflamm Res 52: 95-100.
5. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516.
6. Sundstrom J, Vasan RS (2006) Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol 17: 45-53.
7. Hansson J, Lind L, Hulthe J, Sundstrom J (2009) Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study. Eur J Cardiovasc Prev Rehabil.
8. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, et al. (2004) Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J 25: 1509-1516.
9. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, et al. (2004) Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109: 2850-2856.
10. Garvin P, Nilsson L, Carstensen J, Jonasson L, Kristenson M (2008) Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS One 3: e1774.
11. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, et al. (2006) Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 151: 1101 e1101-1108.
12. Lubos E, Schnabel R, Rupprecht HJ, Bickel C, Messow CM, et al. (2006) Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J 27: 150-156.
13. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, et al. (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107: 1579-1585.
14. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T (2000) Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res 20: 1311-1316.
15. Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, et al. (2008) Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 122: 2050-2056.
16. Yukawa N, Yoshikawa T, Akaike M, Sugimasa Y, Rino Y, et al. (2007) Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology 72: 205-208.
17. Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O (2009) Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer. Gastric Cancer 12: 31-36.
18. Byberg L, Siegbahn A, Berglund L, McKeigue P, Reneland R, et al. (1998) Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Arterioscler Thromb Vasc Biol 18: 258-264.
19. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A (2005) Calculating measures of biological interaction. Eur J Epidemiol 20: 575-579.
20. West MJ, Nestel PJ, Kirby AC, Schnabel R, Sullivan D, et al. (2008) The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J 29: 923-931.
21. Eldrup N, Gronholdt ML, Sillesen H, Nordestgaard BG (2006) Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 114: 1847-1854.
22. Tuomainen AM, Nyyssonen K, Laukkanen JA, Tervahartiala T, Tuomainen TP, et al. (2007) Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 27: 2722-2728.
23. Velagaleti RS, Gona P, Sundstrom J, Larson MG, Siwik D, et al. Relations of Biomarkers of Extracellular Matrix Remodeling to Incident Cardiovascular Events and Mortality. Arterioscler Thromb Vasc Biol.
24. Frantz S, Stork S, Michels K, Eigenthaler M, Ertl G, et al. (2008) Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail 10: 388-395.
25. George J, Patal S, Wexler D, Roth A, Sheps D, et al. (2005) Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase- 9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150: 484-487.
26. Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, et al. (2001) Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32: 1759-1766.
27. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, et al. (2003) Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107: 598-603.
28. Montaner J, Fernandez-Cadenas I, Molina CA, Monasterio J, Arenillas JF, et al. (2003) Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene. Stroke 34: 2851-2855.
29. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, et al. (2003) Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 34: 40-46.
30. Jefferis BJ, Whincup P, Welsh P, Wannamethee G, Rumley A, et al. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 208: 557-563.
31. Rouis M, Adamy C, Duverger N, Lesnik P, Horellou P, et al. (1999) Adenovirusmediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 100: 533-540.
32. Turunen MP, Puhakka HL, Koponen JK, Hiltunen MO, Rutanen J, et al. (2002) Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer. Mol Ther 6: 306-312.
33. Silence J, Collen D, Lijnen HR (2002) Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res 90: 897-903.
34. Luttun A, Lutgens E, Manderveld A, Maris K, Collen D, et al. (2004) Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 109: 1408-1414.
35. Chancey AL, Brower GL, Peterson JT, Janicki JS (2002) Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 105: 1983-1988.
36. Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak H, et al. (1999) Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85: 364-376.
37. Creemers EE, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, et al. (2003) Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 284: H364-371.
38. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, et al. (1999) Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5: 1135-1142.
39. Rouet-Benzineb P, Buhler JM, Dreyfus P, Delcourt A, Dorent R, et al. (1999) Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1: 337-352.
40. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992) Growthpromoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298: 29-32.
41. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES (2004) The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 50: 87-100.
42. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, et al. (2001) Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 69: 851-859.
43. Jung K (2008) Matrix metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in serum do not reflect the analytes circulating in blood. Arterioscler Thromb Vasc Biol 28: e15-16; author reply e17.
44. Rouy D, Ernens I, Jeanty C, Wagner DR (2005) Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem 338: 294-298.
45. Dorman G, Kocsis-Szommer K, Spadoni C, Ferdinandy P (2007) MMP inhibitors in cardiac diseases: an update. Recent Pat Cardiovasc Drug Discov 2: 186-194.